Irinotecan Dosing in Biweekly FOLFIRI
For biweekly FOLFIRI, irinotecan should be dosed at 180 mg/m² IV on day 1, repeated every 2 weeks. This is the established standard dose supported by FDA labeling and international guidelines 1.
Standard FOLFIRI Regimen (Every 2 Weeks)
The complete biweekly FOLFIRI regimen consists of:
- Irinotecan: 180 mg/m² IV over 30-90 minutes on day 1
- Leucovorin: 400 mg/m² IV on day 1
- 5-FU bolus: 400 mg/m² IV bolus on day 1
- 5-FU infusion: 2,400 mg/m² continuous IV infusion over 46-48 hours
This cycle repeats every 14 days 2, 1.
Evidence Base
The 180 mg/m² dose for biweekly irinotecan is derived from pivotal FDA registration trials that demonstrated superior survival outcomes. In Study 2 of the FDA label, patients receiving irinotecan plus infusional 5-FU/LV at this dose achieved a median overall survival of 10.8 months versus 8.5 months with 5-FU/LV alone (p=0.035) 1. The objective response rate was 35% with the combination versus 22% with 5-FU/LV alone.
The 150 mg/m² dose mentioned in some guidelines 2 represents a dose range (150-180 mg/m²), but 180 mg/m² is the standard and preferred dose unless dose reduction is required for toxicity or patient-specific factors.
Dose Intensity Considerations
Research attempting to escalate irinotecan beyond 180 mg/m² (up to 260 mg/m²) showed no clear survival advantage and increased toxicity 3. Conversely, a study comparing FOLFIRI to single-agent irinotecan found similar efficacy but increased toxicity with the full FOLFIRI regimen 4, though this was in the second-line setting after oxaliplatin failure.
Critical Dosing Modifications
UGT1A1 Polymorphisms
Patients who are UGT1A1 poor metabolizers (*28/*28, *6/*6, *6/*28 genotypes) require dose reduction due to elevated risk of severe neutropenia and diarrhea. Consider reducing the starting dose to 150 mg/m² or lower in these patients 1.
Toxicity-Based Adjustments
The median relative dose intensity in clinical trials was 87-95%, indicating frequent dose modifications are necessary 1. Common reasons for reduction include:
- Grade 3/4 neutropenia (occurs in 47-59% of patients)
- Grade 3/4 diarrhea (occurs in 11-18% of patients)
Practical Implementation
Start with 180 mg/m² unless:
- UGT1A1 poor metabolizer status is known → reduce to 150 mg/m² or lower
- Age >70 years with concerns about tolerance → consider 150-180 mg/m² range 5
- Performance status 2 or significant comorbidities → start at 150 mg/m²
The biweekly schedule offers better tolerability than weekly regimens while maintaining efficacy. Studies comparing different 5-FU schedules with irinotecan (bolus Nordic versus infusional de Gramont) showed equivalent progression-free survival and overall survival, though the infusional schedule had fewer hematologic toxicities 6.
Common Pitfalls
- Do not confuse biweekly (every 2 weeks) with weekly dosing schedules - weekly schedules use 125 mg/m² on days 1,8,15,22 every 6 weeks, which is a different regimen entirely 1
- Ensure adequate supportive care including antiemetics, atropine for acute cholinergic symptoms, and loperamide for diarrhea management
- Implement fluoroquinolone prophylaxis if diarrhea persists >24 hours despite loperamide or if fever develops with diarrhea 1